title: Mortality in 7B2 null mice can be rescued by adrenalectomy: involvement of dopamine in ACTH hypersecretion.
abstract: The serine protease prohormone convertase 2 (PC2), principally involved in the processing of polypeptide hormone precursors in neuroendocrine tissues, requires interaction with the neuroendocrine protein 7B2 to generate an enzymatically active form. 7B2 null mice express no PC2 activity and release large quantities of uncleaved ACTH, resulting in a lethal endocrine condition that resembles pituitary Cushing's (Westphal, C. H., Muller, L., Zhou, A., Bonner-Weir, S., Schambelan, M., Steiner, D. F., Lindberg, I. & Leder, P. (1999) Cell 96, 689). Here, we have compared the 7B2 and PC2 null mouse models to determine why the 7B2 null, but not the PC2 null, exhibits a lethal disease state. Both 7B2 and PC2 nulls contained highly elevated pituitary adrenocorticotropic hormone (ACTH); the neurointermediate lobe content of ACTH in 7B2 nulls was 13-fold higher than in WT mice; that of the PC2 null was 65-fold higher. However, circulating ACTH levels were much higher in the 7B2 null than in the PC2 null. Because hypothalamic inhibitory dopaminergic control represents the major influence on intermediate lobe proopiomelanocortin-derived peptide secretion, dopamine levels were measured, and they revealed that 7B2 null pituitaries contained only one-fourth of WT pituitary dopamine. Adrenalectomized 7B2 null animals survived past the usual time of death at 5 weeks; a month after adrenalectomy, they exhibited normal levels of pituitary dopamine, circulating ACTH, and corticosterone. Elevated corticosterone, therefore, seems to play a central role in the lethal phenotype of the 7B2 null, whereas a 7B2-mediated dopaminergic deficiency state may be involved in the actual ACTH hypersecretion phenomenon. Interestingly, adrenalectomized 7B2 nulls also developed unexpectedly severe obesity.
authors.affiliation: Department of Biochemistry and Molecular Biology, and Neuroscience Center, Louisiana State University Health Sciences Center, New Orleans, LA 70112-2223, USA.
authors.forename: V
authors.initials: V
authors.lastname: Laurent
authors.forename: A
authors.initials: A
authors.lastname: Kimble
authors.forename: B
authors.initials: B
authors.lastname: Peng
authors.forename: P
authors.initials: P
authors.lastname: Zhu
authors.forename: J E
authors.initials: JE
authors.lastname: Pintar
authors.forename: D F
authors.initials: DF
authors.lastname: Steiner
authors.forename: I
authors.initials: I
authors.lastname: Lindberg
mesh_terms: D000311:Adrenal Glands / Q000378:metabolism*; D000315:Adrenalectomy; D000324:Adrenocorticotropic Hormone / Q000235:genetics / Q000378:metabolism*; D000818:Animals; D003480:Cushing Syndrome / Q000209:etiology / Q000378:metabolism* / Q000401:mortality; D004298:Dopamine / Q000378:metabolism*; D006801:Humans; D017403:In Situ Hybridization; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D009419:Nerve Tissue Proteins / Q000235:genetics / Q000502:physiology*; D051859:Neuroendocrine Secretory Protein 7B2; D010641:Phenotype; D010902:Pituitary Gland / Q000378:metabolism; D010903:Pituitary Gland, Anterior / Q000378:metabolism; D010907:Pituitary Hormones / Q000235:genetics / Q000502:physiology*; D011333:Pro-Opiomelanocortin / Q000235:genetics; D045706:Proprotein Convertase 2; D012333:RNA, Messenger; D013381:Subtilisins / Q000235:genetics / Q000502:physiology
chemical_list: D009419:Nerve Tissue Proteins; D051859:Neuroendocrine Secretory Protein 7B2; D010907:Pituitary Hormones; D012333:RNA, Messenger; C497678:SCG5 protein, human; D011333:Pro-Opiomelanocortin; D000324:Adrenocorticotropic Hormone; D013381:Subtilisins; D045706:Proprotein Convertase 2; D004298:Dopamine